Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX
Lexicon Pharmaceuticals — Q3 2026 Earnings Presentation
19 slides from Lexicon Pharmaceuticals's earnings presentation, Nov 5, 2026
Slide 1: Third Quarter 2026 Earnings
Third Quarter 2026 Earnings Nove mber 5, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements • This presentation, including any oral presentation accompanying it, contains “forward-looking statements,” including statements about Lexicon’s strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as pr
Slide 3: Q3 2026 Highlights
Q3 2026 Highlights Mike Exton Ph.D. Director and Chief Executive Officer 3
Slide 4: Year-to-Date 2026 Highlights
Overview Year-to-Date 2026 Highlights Advancing our pipeline of novel therapies for serious cardiometabolic diseases SOTAGLIFLOZIN LX9851 PILAVAPADIN HCM T1D Heart Failure — Obesity Diabetic Peripheral Global Expansion Neuropathic Pain - Phase 3 SONATA- - STENO1 (third- - Phase 1 study HCM enrollmen
Slide 5: Sotagliflozin in HCM
Sotagliflozin in HCM Improving cardiac metabolism in HCM by working directly on the heart Enabled by unique SGLT1 mechanistic benefits Many presentations… nHCM one disease oHCM HYPERTROPHIC CARDIOMYOPATHY Characterized by global or The hallmark of Without With localized thickening Obstruction Obstru
Slide 6: Significant Need Remains for Patients with HCM
Sotagliflozin in HCM Significant Need Remains for Patients with HCM >800K ~2/3 SAFE + SIMPLE diagnosed HCM patients of symptomatic patients Strong need for an option that in the U.S.1 are nHCM – many more is safe with simple dosing remain undiagnosed2 POPULATION MOMENTUM TREATMENT GAP ACCESS BARRIER
Slide 7: Pipeline Updates
Pipeline Updates Craig Granowitz, M.D. Ph.D. Senior Vice President and Chief Medical Officer 7
Slide 8: SONATA-HCM Phase 3 Study for Symptomatic HCM
Sotagliflozin in HCM SONATA-HCM Phase 3 Study for Symptomatic HCM Baseline characteristics reflect broad and clinically relevant HCM population Enrollment Complete; Topline Results Q1 2027 • Patient demographics consistent with prior studies of Sotagliflozin 400 mg other agents in HCM and reflect re
Slide 9: Growing Body of Recent Evidence Supports Sotagliflozin in HCM
Sotagliflozin in HCM Growing Body of Recent Evidence Supports Sotagliflozin in HCM Highlights differentiation of dual inhibition compared to SGLT2 alone PRECLINICAL BIOLOGY CLINICAL READTHROUGH HCM CLINICAL PROGRAM AHA 2026 – To Be Presented | University of J Mol Cell Cardiol Plus 2026 | HCM Society
Slide 10: Clinical Data Support ZYNQUISTA's Resubmission
Sotagliflozin in T1D Clinical Data Support ZYNQUISTA’s Resubmission Patient-years of exposure achieved; DKA rates support positive benefit:risk profile inTandem clinical program STENO1 investigator-initiated study FDA-RECOGNIZED OUTCOMES IN T1D FDA RESUBMISSION CRITERIA ACHIEVED 1 HbA1c reduction 1
Slide 11: STENO1 DKA Rates are Low and Comparable to Standard of Care
Sotagliflozin in T1D STENO1 DKA Rates are Low and Comparable to Standard of Care ENROLLMENT SNAPSHOT Randomized patients, DKA rate per Group n 100 patient years Historic Rate in Denmark T1D Patients1 n/a ~1.0 Sotagliflozin 496 ~1.0 Standard of Care 708 ~1.0 Enrollment Summary as of August 30, 2026 N
Slide 12: Pilavapadin Significant Reduction in Body Weight from Baseline
Pilavapadin Significant Reduction in Body Weight from Baseline, Alone and in Combination With Semaglutide % Body Weight Change vs Vehicle 10 0 Pilavapadin drove a 13.9% % Body weight -10 -13.93% reduction alone -20 -25.51% Combined with -30 semaglutide, -40 -31.14% body-weight 0 4 7 11 14 18 21 25 2
Slide 13: Financial Overview
Financial Overview Scott Coiante Chief Financial Officer 13
Slide 14: Q3 2026 Financial Summary
Financials Q3 2026 Financial Summary $ (in millions except per share amounts) As of As of Q3 2026 Q3 2025 September 30, December 31, 2026 2025 Total revenues $11.3 $14.2 Cash, cash equivalents, short- $183.2 $125.2 R&D ($16.2) ($18.8) term investments and restricted cash SG&A ($9.5) ($7.6) Total ope
Slide 15: Q3 2026 Financial Highlights and FY 2026 Guidance
Financials Q3 2026 Financial Highlights and FY 2026 Guidance Q3 2026 Key Full Year 2026 Guidance Financial Highlights Operating Expenses* • Recognized $11.3 million in total revenue • Total 2026 operating expenses expected to be between • Includes third $10 million payment from Novo $100 - $110 mill
Slide 16: Summary
Summary Mike Exton Ph.D. Director and Chief Executive Officer 16
Slide 17: Lexicon is Well Positioned for a Transformational Next 12 Months
Conclusion Lexicon is Well Positioned for a Transformational Next 12 Months • Pivotal Phase 3 readout Q1 2027 • Potential broad HCM label path OUR HCM 01 SOTAGLIFLOZIN HEART FAILURE • Pre-commercial planning and readiness ongoing • Ex-U.S. HF launch progressing VISION • NDA resubmission anticipated
Slide 18: Q&A
Q&A Mike Exton, Ph.D. Craig Granowitz, M.D., Ph.D. Scott Coiante Director and Chief Senior Vice President Senior Vice President and Executive Officer and Chief Medical Officer Chief Financial Officer
Slide 19: Thank You
THANK YOU pharmaceuticals
Lexicon Pharmaceuticals — Q3 2026 Earnings Presentation on 6ix